Hogan Lovells advised March Biosciences on the deal. March Biosciences, an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, closed a...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Mind Medicine Inc. Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), completed its underwritten public offering of 9,285,511 common shares, without value, at an offering...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on the deal. Perspective Therapeutics (NYSE AMERICAN: CATX) has completed an underwritten offering of 51,515,880 shares of its common stock at...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Mind Medicine on the deal. Clinical stage biopharmaceutical company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), completed its underwritten offering of 16,666,667 common shares,...
You must be a Standard 1 Year member to access this content.
Hogan Lovells advised Perspective Therapeutics on a series of strategic transactions. Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) has completed a series of strategic transactions with Lantheus Holdings (NASDAQ:...
You must be a Standard 1 Year member to access this content.
